Promega RNasin™ Ribonuclease Inhibitor: Natural

Catalog No. PR-N2111

Supplier: Promega N2111

Description

Ribonuclease inhibitors with broad-spectrum RNase inhibitory properties. Recombinant and native available. Plus version protects RNA before, during and after heating.

• Broad-Spectrum Inhibition of Common Eukaryotic RNases
• Native, recombinant and oxidation-resistant forms available
• Does not inhibit SP6, T7 or T3 RNA Polymerase; GoScript™ Reverse Transcriptase, AMV or M-MLV Reverse Transcriptase; or Taq DNA polymerase.
• Use in many downstream assays: Inhibits a broad spectrum of eukaryotic RNases over a wide pH range (pH 5-8)
• Maintains inhibitory activity over a wide temperature range

1. 1U.S. Patents 4,966,964, 5,019,556, and 5,266,687; Australian Patents 616881 and 641261, are exclusively licensed to Promega Corporation.
2. U.S. Patent 5,552,302, Australian Patent 646803.

Specifications

• Content And Storage: Store at -20°C.
• Concentration: 20 to 40 U/μL
• Formulation: Amount of RNasin™ RNase inhibitor required to inhibit the activity of 5ng of RNase A by 50%, activity is measured by the inhibition of hydrolysis of Cytidine 2,3'-cyclic Monophosphate by RNase A
• For Use With (Application): RT-PCR, protection of mRNA in cDNA synthesis reactions, in-vitro transcription/translation, Increase yield and activity of polysomes, improvement of in-vitro virus replication, improvement of RNA translation in homologous systems, performing RNase-free Antibody staining, enhancement of RNA yields from Riboprobe™ system RNA synthesis reactions
• Quantity: 2500 U